Cancer Immunology Research

Article	Citations
The Gut Microbiome Is Associated with Clinical Response to Anti–PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer	151
The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer	146
Cancer-Associated Fibroblasts Promote Immunosuppression by Inducing ROS-Generating Monocytic MDSCs in Lung Squamous Cell Carcinoma	129
RIPK3 Orchestrates Fatty Acid Metabolism in Tumor-Associated Macrophages and Hepatocarcinogenesis	125
Fatty Acid Oxidation Controls CD8+ Tissue-Resident Memory T-cell Survival in Gastric Adenocarcinoma	117
Association of Probiotic Clostridium butyricum Therapy with Survival and Response to Immune Checkpoint Blockade in Patients with Lung Cancer	113
Lactate-Modulated Immunosuppression of Myeloid-Derived Suppressor Cells Contributes to the Radioresistance of Pancreatic Cancer	111
The Prognostic Role of Macrophage Polarization in the Colorectal Cancer Microenvironment	94
Paclitaxel Induces Immunogenic Cell Death in Ovarian Cancer via TLR4/IKK2/SNARE-Dependent Exocytosis	91
Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1/PD-L1 Immune Checkpoint Blockade	89
CD39 Identifies the CD4+ Tumor-Specific T-cell Population in Human Cancer	86
CD73 Blockade Promotes Dendritic Cell Infiltration of Irradiated Tumors and Tumor Rejection	84
Identification of the Cryptic HLA-I Immunopeptidome	81
Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy	73
Inhibition of MICA and MICB Shedding Elicits NK-Cell–Mediated Immunity against Tumors Resistant to Cytotoxic T Cells	71
Glioblastoma Cell–Derived lncRNA-Containing Exosomes Induce Microglia to Produce Complement C5, Promoting Chemotherapy Resistance	70
Pharmacologic Screening Identifies Metabolic Vulnerabilities of CD8+ T Cells	70
TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma	69
Immune Escape during Breast Tumor Progression	69
A. Muciniphila Suppresses Colorectal Tumorigenesis by Inducing TLR2/NLRP3-Mediated M1-Like TAMs	65
Lighting a Fire: Can We Harness Pyroptosis to Ignite Antitumor Immunity?	63
Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer	60
Verteporfin Inhibits PD-L1 through Autophagy and the STAT1–IRF1–TRIM28 Signaling Axis, Exerting Antitumor Efficacy	60
KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1	55
Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments	55

Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors	52
B7-H3 Suppresses Antitumor Immunity via the CCL2–CCR2–M2 Macrophage Axis and Contributes to Ovarian Cancer Progression	52
CD226hiCD8+ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy	52
Transfer of MicroRNA via Macrophage-Derived Extracellular Vesicles Promotes Proneural-to-Mesenchymal Transition in Glioma Stem Cells	51
Exercise Training Improves Tumor Control by Increasing CD8+ T-cell Infiltration via CXCR3 Signaling and Sensitizes Breast Cancer to Immune Checkpoint Blockade	51
Proteogenomics Uncovers a Vast Repertoire of Shared Tumor-Specific Antigens in Ovarian Cancer	48
Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors	47
Anti-VEGF Treatment Enhances CD8+ T-cell Antitumor Activity by Amplifying Hypoxia	47
IL1β Promotes Immune Suppression in the Tumor Microenvironment Independent of the Inflammasome and Gasdermin D	45
SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti–PD-1–Resistant Model of Non–Small Cell Lung Cancer	44
Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer	44
The Expression of Adenosine A2B Receptor on Antigen-Presenting Cells Suppresses CD8+ T-cell Responses and Promotes Tumor Growth	43
Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma	43
Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s	42
Chronic Adrenergic Stress Contributes to Metabolic Dysfunction and an Exhausted Phenotype in T Cells in the Tumor Microenvironment	42
Insights into Tumor-Associated Tertiary Lymphoid Structures: Novel Targets for Antitumor Immunity and Cancer Immunotherapy	41
Intratumoral Delivery of a PD-1–Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade	41
Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade	40
Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity	40
CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement	39
The Mincle/Syk/NF-κB Signaling Circuit Is Essential for Maintaining the Protumoral Activities of Tumor-Associated Macrophages	39
Chemotherapeutic Tumor Microparticles Elicit a Neutrophil Response Targeting Malignant Pleural Effusions	39
Tenascin-C Orchestrates an Immune-Suppressive Tumor Microenvironment in Oral Squamous Cell Carcinoma	39
ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity	39
Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer	39
Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype	38
γδ T-cell Receptors Derived from Breast Cancer–Infiltrating T Lymphocytes Mediate Antitumor Reactivity	38
Potent Cytolytic Activity and Specific IL15 Delivery in a Second-Generation Trispecific Killer Engager	38
Circadian Regulator CLOCK Drives Immunosuppression in Glioblastoma	37
Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity	37
Overproduction of Gastrointestinal 5-HT Promotes Colitis-Associated Colorectal Cancer Progression via Enhancing NLRP3 Inflammasome Activation	37
Long Noncoding RNAs Control the Modulation of Immune Checkpoint Molecules in Cancer	36
CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study	36
CD86+ Antigen-Presenting B Cells Are Increased in Cancer, Localize in Tertiary Lymphoid Structures, and Induce Specific T-cell Responses	36
Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition	36
Blocking P2X7-Mediated Macrophage Polarization Overcomes Treatment Resistance in Lung Cancer	35
Hallmarks of Resistance to Immune-Checkpoint Inhibitors	35
A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy	35
Single-Cell Analysis of the Pan-Cancer Immune Microenvironment and scTIME Portal	34
Demographic Factors Associated with Toxicity in Patients Treated with Anti–Programmed Cell Death-1 Therapy	34
Glycans as Immune Checkpoints: Removal of Branched N-glycans Enhances Immune Recognition Preventing Cancer Progression	33
An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity	33
Myeloid-Derived Suppressor Cells and Radiotherapy	33
Fueling T-cell Antitumor Immunity: Amino Acid Metabolism Revisited	33
An IL6–Adenosine Positive Feedback Loop between CD73+ γδTregs and CAFs Promotes Tumor Progression in Human Breast Cancer	32
Hyperglycemia Enhances Cancer Immune Evasion by Inducing Alternative Macrophage Polarization through Increased O-GlcNAcylation	32
Chemotherapy Induces Tumor-Associated Macrophages that Aid Adaptive Immune Responses in Ovarian Cancer	31
LncRNAAK036396Inhibits Maturation and Accelerates Immunosuppression of Polymorphonuclear Myeloid–Derived Suppressor Cells by Enhancing the Stability of Ficolin B	31
Radiotherapy Cooperates with IL15 to Induce Antitumor Immune Responses	30
CD28 Costimulatory Domain–Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function	30

CAR T-cell Entry into Tumor Islets Is a Two-Step Process Dependent on IFNγ and ICAM-1	30
Arginase 1–Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti–PD-1 Checkpoint Blockade	30
MHC Class II Antigen Presentation by Lymphatic Endothelial Cells in Tumors Promotes Intratumoral Regulatory T cell–Suppressive Functions	30
Checkpoint Blockade–Induced Dermatitis and Colitis Are Dominated by Tissue-Resident Memory T Cells and Th1/Tc1 Cytokines	29
Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy	29
Gut Microbiota and Antitumor Immunity: Potential Mechanisms for Clinical Effect	29
PRDX-1 Supports the Survival and Antitumor Activity of Primary and CAR-Modified NK Cells under Oxidative Stress	28
Combination Neoantigen-Based Dendritic Cell Vaccination and Adoptive T-Cell Transfer Induces Antitumor Responses Against Recurrence of Hepatocellular Carcinoma	28
Activating Mucosal-Associated Invariant T Cells Induces a Broad Antitumor Response	28
Modified Hypoxia-Inducible Factor Expression in CD8+ T Cells Increases Antitumor Efficacy	28
Mechanisms Driving Neutrophil-Induced T-cell Immunoparalysis in Ovarian Cancer	28
Tumor-Infiltrating Regulatory T-cell Accumulation in the Tumor Microenvironment Is Mediated by IL33/ST2 Signaling	27
Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8+ T Cells within Polyomavirus-Driven Merkel Cell Carcinomas	27
Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses	27
Metabolome of Pancreatic Juice Delineates Distinct Clinical Profiles of Pancreatic Cancer and Reveals a Link between Glucose Metabolism and PD-1+ Cells	26
Gastric Microbiome Alterations Are Associated with Decreased CD8+ Tissue-Resident Memory T Cells in the Tumor Microenvironment of Gastric Cancer	26
Tumor-Derived IL33 Promotes Tissue-Resident CD8+ T Cells and Is Required for Checkpoint Blockade Tumor Immunotherapy	26
Enzalutamide, an Androgen Receptor Antagonist, Enhances Myeloid Cell–Mediated Immune Suppression and Tumor Progression	26
Immunotargeting of the xCT Cystine/Glutamate Antiporter Potentiates the Efficacy of HER2-Targeted Immunotherapies in Breast Cancer	26
A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation	26
Human NKp44+ Group 3 Innate Lymphoid Cells Associate with Tumor-Associated Tertiary Lymphoid Structures in Colorectal Cancer	26
Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2+ Breast Tumor Microenvironment	26
NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy	25
Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling	25
The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma	25
Kindlin3-Dependent CD11b/CD18-Integrin Activation Is Required for Potentiation of Neutrophil Cytotoxicity by CD47–SIRPα Checkpoint Disruption	25
Targeting the Siglec–Sialic Acid Immune Axis in Cancer: Current and Future Approaches	25
Identification of the Targets of T-cell Receptor Therapeutic Agents and Cells by Use of a High-Throughput Genetic Platform	25
The IKZF1–IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages	25
Tumor Cell–Derived TGFβ1 Attenuates Antitumor Immune Activity of T Cells via Regulation of PD-1 mRNA	25
cDC1 Vaccines Drive Tumor Rejection by Direct Presentation Independently of Host cDC1	25
Cross-dressing of CD8α+ Dendritic Cells with Antigens from Live Mouse Tumor Cells Is a Major Mechanism of Cross-priming	24
Inhibition of the SRC Kinase HCK Impairs STAT3-Dependent Gastric Tumor Growth in Mice	24
Discovery of a Conditionally Activated IL-2 that Promotes Antitumor Immunity and Induces Tumor Regression	24
The SETDB1–TRIM28 Complex Suppresses Antitumor Immunity	24
Inhibition of SHP-1 Expands the Repertoire of Antitumor T Cells Available to Respond to Immune Checkpoint Blockade	23
The Fibronectin–ILT3 Interaction Functions as a Stromal Checkpoint that Suppresses Myeloid Cells	23
Quantification of Early-Stage Myeloid-Derived Suppressor Cells in Cancer Requires Excluding Basophils	23
Activation of Tumor-Cell STING Primes NK-Cell Therapy	23
A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell–Mediated Antitumor Responses in Human B-cell Malignancies	23
Targeting PIM1-Mediated Metabolism in Myeloid Suppressor Cells to Treat Cancer	23
Antitumor Effects of CAR T Cells Redirected to the EDB Splice Variant of Fibronectin	23
Spatial Organization and Prognostic Significance of NK and NKT-like Cells via Multimarker Analysis of the Colorectal Cancer Microenvironment	22
Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients	22
Nutlin-3a Enhances Natural Killer Cell–Mediated Killing of Neuroblastoma by Restoring p53-Dependent Expression of Ligands for NKG2D and DNAM-1 Receptors	22
Host IL11 Signaling Suppresses CD4+ T cell–Mediated Antitumor Responses to Colon Cancer in Mice	22
Molecular Subgroups of Intrahepatic Cholangiocarcinoma Discovered by Single-Cell RNA Sequencing–Assisted Multiomics Analysis	22
Sialylation of CD55 by ST3GAL1 Facilitates Immune Evasion in Cancer	22
γδ T Cells in Merkel Cell Carcinomas Have a Proinflammatory Profile Prognostic of Patient Survival	22
DKK1 Promotes Tumor Immune Evasion and Impedes Anti–PD-1 Treatment by Inducing Immunosuppressive Macrophages in Gastric Cancer	21
Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma	21
An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression	21
Holistic Characterization of Tumor Monocyte-to-Macrophage Differentiation Integrates Distinct Immune Phenotypes in Kidney Cancer	21
Immunosuppressive Mediators Impair Proinflammatory Innate Lymphoid Cell Function in Human Malignant Melanoma	21
CSF1R Is Required for Differentiation and Migration of Langerhans Cells and Langerhans Cell Histiocytosis	20
Preclinical Characterization of Relatlimab, a Human LAG-3–Blocking Antibody, Alone or in Combination with Nivolumab	20
Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies	20
Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity	20
CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer	20
Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity	20
At the Crossroads: COVID-19 and Immune-Checkpoint Blockade for Cancer	20
A DNA-Launched Nanoparticle Vaccine Elicits CD8+ T-cell Immunity to Promote In Vivo Tumor Control	20
Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors	19
ST8Sia6 Promotes Tumor Growth in Mice by Inhibiting Immune Responses	19
Treg-Dominant Tumor Microenvironment Is Responsible for Hyperprogressive Disease after PD-1 Blockade Therapy	19
Macrophage-Targeted Therapy Unlocks Antitumoral Cross-talk between IFNγ-Secreting Lymphocytes and IL12-Producing Dendritic Cells	19
Immune-Guided Therapy of COVID-19	19
CD40 Agonist Restores the Antitumor Efficacy of Anti-PD1 Therapy in Muscle-Invasive Bladder Cancer in an IFN I/II-Mediated Manner	19
Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved	19
Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens	18
DGKA Mediates Resistance to PD-1 Blockade	18
Targeting the Atf7ip–Setdb1 Complex Augments Antitumor Immunity by Boosting Tumor Immunogenicity	18
Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition	18
Fructose Promotes Cytoprotection in Melanoma Tumors and Resistance to Immunotherapy	18
APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell–Mediated Antitumor Immune Responses	18
Tumor-Associated Neutrophils Drive B-cell Recruitment and Their Differentiation to Plasma Cells	17
Oxidized Lipoproteins Promote Resistance to Cancer Immunotherapy Independent of Patient Obesity	17
NKG7 Is Required for Optimal Antitumor T-cell Immunity	17
Remodeling Translation Primes CD8+ T-cell Antitumor Immunity	17
Optimization of T-cell Receptor–Modified T Cells for Cancer Therapy	17

Fueling the Revolution: Targeting Metabolism to Enhance Immunotherapy	17
Immunosuppressive Myeloid Cells Induce Nitric Oxide–Dependent DNA Damage and p53 Pathway Activation in CD8+ T Cells	17
CRASH-IT Switch Enables Reversible and Dose-Dependent Control of TCR and CAR T-cell Function	17
The Ratio of Exhausted to Resident Infiltrating Lymphocytes Is Prognostic for Colorectal Cancer Patient Outcome	17
CAMK1D Triggers Immune Resistance of Human Tumor Cells Refractory to Anti–PD-L1 Treatment	17
Excessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells	17
Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses	17
Histone Deacetylase Inhibitors and IL21 Cooperate to Reprogram Human Effector CD8+ T Cells to Memory T Cells	16
Engineered T-cell Receptor T Cells for Cancer Immunotherapy	16
Dual Relief of T-lymphocyte Proliferation and Effector Function Underlies Response to PD-1 Blockade in Epithelial Malignancies	16
Pharmacologic Inhibition of FGFR Modulates the Metastatic Immune Microenvironment and Promotes Response to Immune Checkpoint Blockade	16
CD8+ T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA PVT1	16
Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia	16
BHLHE40 Regulates the T-Cell Effector Function Required for Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy	16
PD-1/PD-L1–Associated Immunoarchitectural Patterns Stratify Pancreatic Cancer Patients into Prognostic/Predictive Subgroups	16
Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity	15
CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function	15
Immune Remodeling of the Extracellular Matrix Drives Loss of Cancer Stem Cells and Tumor Rejection	15
Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents	15
Arid5a Promotes Immune Evasion by Augmenting Tryptophan Metabolism and Chemokine Expression	15
Infiltration by IL22-Producing T Cells Promotes Neutrophil Recruitment and Predicts Favorable Clinical Outcome in Human Colorectal Cancer	15
IDO1 Signaling through GCN2 in a Subpopulation of Gr-1+ Cells Shifts the IFNγ/IL6 Balance to Promote Neovascularization	15
Dysregulated NF-κB–Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma	15
Targeted Therapy Given after Anti–PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity	15
Retinoic Acid Synthesis Deficiency Fosters the Generation of Polymorphonuclear Myeloid-Derived Suppressor Cells in Colorectal Cancer	15
Pro- and Antitumorigenic Capacity of Immunoproteasomes in Shaping the Tumor Microenvironment	14
Superkine IL-2 and IL-33 Armored CAR T Cells Reshape the Tumor Microenvironment and Reduce Growth of Multiple Solid Tumors	14
Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade	14
IL18 Receptor Signaling Regulates Tumor-Reactive CD8+ T-cell Exhaustion via Activation of the IL2/STAT5/mTOR Pathway in a Pancreatic Cancer Model	14
Hijacking TYRO3 from Tumor Cells via Trogocytosis Enhances NK-cell Effector Functions and Proliferation	14
Notch-Regulated Dendritic Cells Restrain Inflammation-Associated Colorectal Carcinogenesis	13
Site-Dependent Immune Escape Due to Impaired Dendritic Cell Cross-Priming	13
Transient Depletion of CD4+ Cells Induces Remodeling of the TCR Repertoire in Gastrointestinal Cancer	13
PBRM1 Inactivation Promotes Upregulation of Human Endogenous Retroviruses in a HIF-Dependent Manner	13
Navigating Critical Challenges Associated with Immunopeptidomics-Based Detection of Proteasomal Spliced Peptide Candidates	13
Long Noncoding RNA MIR4435-2HG Suppresses Colorectal Cancer Initiation and Progression By Reprogramming Neutrophils	13
Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas	13
Targeting the PSGL-1 Immune Checkpoint Promotes Immunity to PD-1–Resistant Melanoma	13
P2RX7 Enhances Tumor Control by CD8+ T Cells in Adoptive Cell Therapy	13
Longitudinal Immune Profiling Reveals Unique Myeloid and T-cell Phenotypes Associated with Spontaneous Immunoediting in a Prostate Tumor Model	12
Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer	12
Vaccination against Nonmutated Neoantigens Induced in Recurrent and Future Tumors	12
Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers	12
Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma	12
Mitochondria as Playmakers of CAR T-cell Fate and Longevity	12
Radiofrequency Ablation Remodels the Tumor Microenvironment and Promotes Neutrophil-Mediated Abscopal Immunomodulation in Pancreatic Cancer	12
Sensory Nerves Impede the Formation of Tertiary Lymphoid Structures and Development of Protective Antimelanoma Immune Responses	12
Flightless I Homolog Reverses Enzalutamide Resistance through PD-L1–Mediated Immune Evasion in Prostate Cancer	12
Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic Cancer	12
IL1α Antagonizes IL1β and Promotes Adaptive Immune Rejection of Malignant Tumors	12
Oncogenic KIT Modulates Type I IFN–Mediated Antitumor Immunity in GIST	12
A Costimulatory CAR Improves TCR-based Cancer Immunotherapy	12
Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer	12
The Conventional Dendritic Cell 1 Subset Primes CD8+ T Cells and Traffics Tumor Antigen to Drive Antitumor Immunity in the Brain	11
Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T	11
Myeloma-Secreted Galectin-1 Potently Interacts with CD304 on Monocytic Myeloid-Derived Suppressor Cells	11
Comprehensive Characterizations of Immune Receptor Repertoire in Tumors and Cancer Immunotherapy Studies	11
Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer	11
Arginase Therapy Combines Effectively with Immune Checkpoint Blockade or Agonist Anti-OX40 Immunotherapy to Control Tumor Growth	11
Targeting WEE1/AKT Restores p53-Dependent Natural Killer–Cell Activation to Induce Immune Checkpoint Blockade Responses in “Cold” Melanoma	11
Using CD69 PET Imaging to Monitor Immunotherapy-Induced Immune Activation	11
Therapy of Established Tumors with Rationally Designed Multiple Agents Targeting Diverse Immune–Tumor Interactions: Engage, Expand, Enable	11
Extracellular Vesicle–Packaged circATP2B4 Mediates M2 Macrophage Polarization via miR-532-3p/SREBF1 Axis to Promote Epithelial Ovarian Cancer Metastasis	11
TGFβ and CIS Inhibition Overcomes NK-cell Suppression to Restore Antitumor Immunity	11
The Tumor Microenvironment of Clear-Cell Ovarian Cancer	11
A Population of TIM4+FOLR2+ Macrophages Localized in Tertiary Lymphoid Structures Correlates to an Active Immune Infiltrate Across Several Cancer Types	11
Combining an Alarmin HMGN1 Peptide with PD-L1 Blockade Results in Robust Antitumor Effects with a Concomitant Increase of Stem-Like/Progenitor Exhausted CD8+ T Cells	11
Integrin β7 Inhibits Colorectal Cancer Pathogenesis via Maintaining Antitumor Immunity	11
Effective Treatment of Established Bone Metastases Can Be Achieved by Combinatorial Osteoclast Blockade and Depletion of Granulocytic Subsets	11
ICBatlas: A Comprehensive Resource for Depicting Immune Checkpoint Blockade Therapy Characteristics from Transcriptome Profiles	11
IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status	11
Molecular Signature of Tumor-Associated High Endothelial Venules That Can Predict Breast Cancer Survival	11
Distinctive Subpopulations of Stromal Cells Are Present in Human Lymph Nodes Infiltrated with Melanoma	10
Understanding and Overcoming the Inflammatory Toxicities of Immunotherapy	10
CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in Egfr-Mutant Lung Cancer	10
Idelalisib Rescues Natural Killer Cells from Monocyte-Induced Immunosuppression by Inhibiting NOX2-Derived Reactive Oxygen Species	10
Inflammation-Induced Abnormal Expression of Self-molecules on Epithelial Cells: Targets for Tumor Immunoprevention	10
Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers	10
Improved T-cell Receptor Diversity Estimates Associate with Survival and Response to Anti–PD-1 Therapy	10
Mystery Checkpoint Revealed: KIR3DL3 Finally Found a Ligand in HHLA2	10
Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8+ T Cells	10
Netrin-1 Promotes the Immunosuppressive Activity of MDSCs in Colorectal Cancer	10
Accounting for B-cell Behavior and Sampling Bias Predicts Anti–PD-L1 Response in Bladder Cancer	10
The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing CancerIn VitroandIn Vivo	10
β2-Integrin Adhesion Regulates Dendritic Cell Epigenetic and Transcriptional Landscapes to Restrict Dendritic Cell Maturation and Tumor Rejection	10
Tumor-Derived Lactic Acid Modulates Activation and Metabolic Status of Draining Lymph Node Stroma	10
Immunomodulation of T- and NK-cell Responses by a Bispecific Antibody Targeting CD28 Homolog and PD-L1	10
Context-Dependent Immunomodulatory Effects of MEK Inhibition Are Enhanced with T-cell Agonist Therapy	10
Imaging of T-cell Responses in the Context of Cancer Immunotherapy	9
GITR Agonism Triggers Antitumor Immune Responses through IL21-Expressing Follicular Helper T Cells	9
Neoadjuvant STING Activation, Extended Half-life IL2, and Checkpoint Blockade Promote Metastasis Clearance via Sustained NK-cell Activation	9
Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti–PD-1 in Metastatic Non–Small Cell Lung Cancer	9
Simultaneous Engagement of Tumor and Stroma Targeting Antibodies by Engineered NK-92 Cells Expressing CD64 Controls Prostate Cancer Growth	9
A Machine Learning Approach Yields a Multiparameter Prognostic Marker in Liver Cancer	9
A Multispecific Anti-CD40 DARPin Construct Induces Tumor-Selective CD40 Activation and Tumor Regression	9